Management ChangeApr 10, 2026, 04:06 PM
Bruker BioSpin President Falko Busse to Depart
AI Summary
Falko Busse, Ph.D., an executive officer of Bruker Corporation and President of its wholly owned subsidiary Bruker BioSpin Group, will transition from his duties around May 1, 2026, with his employment officially terminating on October 31, 2026. In connection with his departure, Dr. Busse will receive separation benefits, including severance, a pro-rated bonus, and unused vacation payout, totaling approximately $1,020,351. However, he will forfeit any unvested equity awards he holds on the separation date.
Key Highlights
- Falko Busse, President of Bruker BioSpin, will depart the company.
- His executive officer duties will transition around May 1, 2026.
- Employment with Bruker Corporation will terminate on October 31, 2026.
- Dr. Busse will receive separation benefits totaling approximately $1,020,351.
- He will forfeit any unvested equity awards upon his separation date.
Price Impact
More from BRKR